3A5F200F-C6E0-487B-9C3D-BB32C65480E8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.9566360052562417
- age_years
- 43
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- PANCREAS_BETA_CELLS+0.419
- MYC_TARGETS_V2+0.374
- G2M_CHECKPOINT+0.369
- DNA_REPAIR+0.329
- INTERFERON_ALPHA_RESPONSE+0.300
- MYC_TARGETS_V1+0.291
- WNT_BETA_CATENIN_SIGNALING+0.247
- HEDGEHOG_SIGNALING+0.166
- MITOTIC_SPINDLE+0.143
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.381
- APICAL_JUNCTION-0.261
- MYOGENESIS-0.238
- HEME_METABOLISM-0.234
- HYPOXIA-0.231
- ANGIOGENESIS-0.227
- COAGULATION-0.210
- KRAS_SIGNALING_DN-0.207
- ESTROGEN_RESPONSE_EARLY-0.200
- ESTROGEN_RESPONSE_LATE-0.197
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 431EAB8C-D0B4-4440-A2B6-1D001B0026E2 | — | — | 0.845 |
| 2 | 74897E26-10A5-4484-A867-CE7C86DDB7E2 | — | — | 0.836 |
| 3 | 3E5F6B52-112E-4F87-B49C-061B9DFD1E2D | — | — | 0.805 |
| 4 | BS_TGS109T3 | high-grade glioma | — | 0.805 |
| 5 | 293E6D35-8392-4C44-BC18-F917989516B0 | — | — | 0.801 |
| 6 | aMVAC.P_011_TURBT_S228 | — | — | 0.797 |
| 7 | BS_B1C6GZ84 | Diffuse intrinsic pontine glioma | — | 0.795 |
| 8 | 848C73F3-ABD7-47FD-BF70-FF29FBDF6F61 | — | — | 0.791 |
| 9 | 86379365-5FD2-4655-8B3C-B8E0EE25EE92 | — | — | 0.764 |
| 10 | SRR8518219 | — | E | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.419 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.374 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.369 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.329 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.291 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.247 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.166 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.143 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.139 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.104 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.071 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.067 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.048 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.042 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.029 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.028 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.011 | Remibrutinib | — uncovered |